Thoughts on DESTINY-Breast04 for HER2-low metastatic breast cancer.

Joseph GLIGOROV
Oncologist, Paris, France
CONTINUE READING

Updated HR+/HER2- metastatic management.

Hassan GHAZAL
Oncologist, Dubai, UAE
CONTINUE READING

New drugs and options in MBC: Are there drugs that must be offered to patients in 2023?

Joseph GLIGOROV
Oncologist, Paris, France
CONTINUE READING

Molecular profiling of breast cancers.

Benjamin VERRET
Oncologist, Villejuif, France
CONTINUE READING

New treatments and perspectives in metastatic TNBC with PARP Inhibitors.

Benjamin VERRET
Oncologist, Villejuif, France
CONTINUE READING

Conjugated antibodies.

Joseph GLIGOROV
Oncologist, Paris, France
CONTINUE READING

Therapeutic options and systemic therapy.

Joseph GLIGOROV
Oncologist, Paris, France
CONTINUE READING

Thoughts on DESTINY-Breast04 for HER2-low metastatic breast cancer.

Joseph GLIGOROV
Oncologist, Paris, France
CONTINUE READING

Copyright © 2026 - BCU